.jpg "Amal Mansour, MD, PhD, MSc. photo")
Principal Scientist
BMS
Amal Mansour, MD, PhD, MSc., Principal Scientist Molecular Genetics and Genomics in precision medicine at Bristol Myers Squibb, Lawrenceville, NJ.
Dr. Mansour graduated from Alexandria University Faculty of Medicine and completed a medical residency in Clinical Pathology followed by a fellowship in Hematopathology in Egypt. She was granted the PhD in Molecular Pathology and Immunology from UMDNJ-Rutgers University Newark, NJ. Dr. Mansour completed a fellowship in Translational Oncology at the Cancer Instute of New Jersey where she collaborated on the development of a recombinant tumor vaccine in a phase I/II bladder cancer clinical trial, and was granted the NJ Cancer Research Award for Scientific Excellence from NJCCR. She has been working as an Associate Professor of Clinical Pathology at Alexandria University and a director of Asafra molecular oncolgy diagnostic laboratory for 10 years. Dr. Mansour then joined the molecualr pathology lab at University of Virginia UVA as a senior scientist, where she established a liquid biopsy assay for the detection of EGFR mutations, to compare EGFR status in tumor versus plasma specimens in 30 NSCLC patients. She also developed a NGS-based assay for ctDNA, which broadened the ctDNA mutation detection ability and increased the clinical utility of this approach. Currently, Dr. Mansour is a principal scientist at BMS Pharmaceuticals. Her role includes but is not limited to providing innovative solutions, precision translational development and diagnostics, supporting pharmacogenetic biomarker development to inform Genetics and Genomic clinical programs, with extensive Immuno-Oncology and Hematology experience and troubleshooting skills.
Cerificates
- MD-ECFMG Certificate (Educational Commission of Foreign Medical Graduates)
- NY Certificate of Qualification CQ code MANSA1 as Clinical Laboratory Director Molecular genetic testing, Immunophenotyping, Oncology, and cellular immunology
Research Interest
Development of the biomarker strategy based on in-depth knowledge of the pathogenesis of hematological malignancies and the bone marrow Tumor microenvironment TME.